Get started
Author

Adeel Masood

Observed names: ADEEL MASOOD, Masood Adeel
ORCID: 0000-0001-7085-777X
Observed ORCID: 0000-0001-7085-777X
OpenAlex ID: A5038186608
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
2021 · Ahsan Wahab, Abdul Rafae, et al. · Frontiers in Oncology · 93
PDF
Treatment of Light Chain Deposition Disease: A Systematic Review
2022 · Adeel Masood, Hamid Ehsan, et al. · Journal of Hematology · 21
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma
2023 · Oren Pasvolsky, Sassine Ghanem, et al. · Transplantation and Cellular Therapy · 17
Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report
2021 · Adeel Masood, Ahsan Wahab, et al. · Clinical Case Reports · 17
PDF
Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature
2022 · Adeel Masood, Ahsan Wahab, et al. · Bone Marrow Transplantation · 15
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
2024 · Oren Pasvolsky, Rima M. Saliba, et al. · Clinical Lymphoma Myeloma & Leukemia · 14
Leukemic stem cells and advances in hematopoietic stem cell transplantation for acute myeloid leukemia: a narrative review of clinical trials
2022 · Vikram Sumbly, Ian Landry, et al. · Stem Cell Investigation · 14
PDF
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
2023 · Oren Pasvolsky, Denái R. Milton, et al. · Blood Cancer Journal · 12
PDF
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature
2022 · Noureen Asghar, Adeel Masood, et al. · Clinical Lymphoma Myeloma & Leukemia · 12
Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma
2022 · Oren Pasvolsky, Denái R. Milton, et al. · Transplantation and Cellular Therapy · 12
Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
2021 · Karun Neupane, Ahsan Wahab, et al. · Journal of Blood Medicine · 12
PDF
Single‐agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience
2023 · Oren Pasvolsky, Denái R. Milton, et al. · American Journal of Hematology · 11
PDF
Zinc-induced hypocupremia and pancytopenia, from zinc supplementation to its toxicity, a case report
2021 · Ahsan Wahab, Kamran Mushtaq, et al. · Journal of Community Hospital Internal Medicine Perspectives · 11
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience
2023 · Oren Pasvolsky, Mahmoud R. Gaballa, et al. · Transplantation and Cellular Therapy · 10
Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant
2023 · Oren Pasvolsky, Rima M. Saliba, et al. · British Journal of Haematology · 8
PDF
Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
2021 · Hamid Ehsan, Ahsan Wahab, et al. · Journal of Hematology · 7
Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis
2022 · Razwana Khanam, Moazzam Shahzad, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 6
Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature
2022 · Adeel Masood, Qamar Iqbal, et al. · Annals of Hematology · 4
Cardiovascular (CV) Mortality Among Adults Diagnosed with Leukemias: A Retrospective Cohort Study
2023 · Ahsan Ayaz, Syed Arsalan Naqvi, et al. · Blood · 2
PDF
Association of medical uninsurance with sociodemographic attributes in US cancer population: A cross-sectional study of NHANES data 2013 to 2018
2022 · Ahsan Wahab, Basel Abdelazeem, et al. · Medicine · 2
Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
2022 · Hamid Ehsan, Qamar Iqbal, et al. · Leukemia Research Reports · 2
PDF
Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review
2021 · Hamid Ehsan, Abdul Rafae, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
2022 · Oren Pasvolsky, Denái R Milton, et al. · Blood · 1
R-CHOP Versus R-EPOCH in Primary Mediastinal Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
2022 · Mohammad Ebad Ur Rehman, Rabia Ali, et al. · Blood · 1
Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
2022 · Oren Pasvolsky, Rima M. Saliba, et al. · Blood · 1
Works count: 45
Citation count: 312
H-index: 11
I10-index: 14
Year
Topic
Type